DOCSLIB.ORG

Hypertrophic Cardiomyopathy: a Systematic Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hypertrophic Cardiomyopathy: a Systematic Review CLINICAL CARDIOLOGY CLINICIAN’S CORNER Hypertrophic Cardiomyopathy A Systematic Review Barry J. Maron, MD Context Throughout the past 40 years, a vast and sometimes contradictory litera- ture has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic car- YPERTROPHIC CARDIOMYOP- diac disease caused by a variety of mutations in genes encoding sarcomeric proteins athy (HCM) is a complex and and characterized by a broad and expanding clinical spectrum. relatively common genetic Objectives To clarify and summarize the relevant clinical issues and to profile rap- cardiac disease that has been idly evolving concepts regarding HCM. Hthe subject of intense scrutiny and in- Data Sources Systematic analysis of the relevant HCM literature, accessed through vestigation for more than 40 years.1-10 Hy- MEDLINE (1966-2000), bibliographies, and interactions with investigators. pertrophic cardiomyopathy is an impor- Study Selection and Data Extraction Diverse information was assimilated into tant cause of disability and death in a rigorous and objective contemporary description of HCM, affording greatest weight patients of all ages, although sudden and to prospective, controlled, and evidence-based studies. unexpected death in young people is per- Data Synthesis Hypertrophic cardiomyopathy is a relatively common genetic car- haps the most devastating component of diac disease (1:500 in the general population) that is heterogeneous with respect to disease- its natural history. Because of marked causing mutations, presentation, prognosis, and treatment strategies. Visibility at- heterogeneity in clinical expression, tached to HCM relates largely to its recognition as the most common cause of sudden natural history, and prognosis,11-20 HCM death in the young (including competitive athletes). Clinical diagnosis is by 2-dimen- often represents a dilemma to primary sional echocardiographic identification of otherwise unexplained left ventricular wall thick- care clinicians and cardiovascular spe- ening in the presence of a nondilated cavity. Overall, HCM confers an annual mortality rate of about 1% and in most patients is compatible with little or no disability and nor- cialists, even to those for whom this dis- mal life expectancy. Subsets with higher mortality or morbidity are linked to the com- ease is a focus of their investigative ca- plications of sudden death, progressive heart failure, and atrial fibrillation with embolic reers. Controversy abounds with regard stroke. Treatment strategies depend on appropriate patient selection, including drug treat- to diagnostic criteria, clinical course, and ment for exertional dyspnea (␤-blockers, verapamil, disopyramide) and the septal myotomy- management for which difficult ques- myectomy operation, which is the standard of care for severe refractory symptoms as- tions often arise, particularly among prac- sociated with marked outflow obstruction; alcohol septal ablation and pacing are alternatives titioners infrequently engaged in the to surgery for selected patients. High-risk patients may be treated effectively for sudden evaluation of HCM patients. Conse- death prevention with the implantable cardioverter-defibrillator. quently, it is timely to place in perspec- Conclusions Substantial understanding has evolved regarding the epidemiology and tive and clarify many of these relevant clinical course of HCM, as well as novel treatment strategies that may alter its natural clinical issues and profile the rapidly history. An appreciation that HCM, although an important cause of death and dis- evolving concepts regarding HCM. ability at all ages, does not invariably convey ominous prognosis and is compatible with normal longevity should dictate a large measure of reassurance for many patients. METHODS JAMA. 2002;287:1308-1320 www.jama.com A systematic search of the medical lit- erature involving 968 articles primar- tively small group of highly selected cen- sion, selective referral patterns, and di- ily related to English-language HCM ters in the United States, Canada, and Eu- verse mechanisms for morbidity and publications (1966-2000) from a var- rope. In addition, perceptions emanating mortality. Therefore, in HCM, the level ied and extensive number of authors from the author’s more than 25 years of of evidence governing management and centers was conducted through extensive experience with HCM inter- MEDLINE or bibliographies of pub- faced with the literature analysis. Many Author Affiliation: Minneapolis Heart Institute Foun- lished articles. These studies and oth- clinical HCM studies are observational dation, Minneapolis, Minn. Corresponding Author and Reprints: Barry J. ers before 1966 were analyzed to cre- and retrospective in design because of Maron, MD, Minneapolis Heart Institute Founda- ate a balanced appraisal of HCM. difficulty in organizing large prospec- tion, 920 E 28th St, Suite 60, Minneapolis, MN 55407 (e-mail: [email protected]). Published accounts of HCM have tive and randomized clinical trials for Clinical Cardiology Section Editor: Michael S. Lauer, come disproportionately from a rela- a disease with heterogeneous expres- MD, Contributing Editor. 1308 JAMA, March 13, 2002—Vol 287, No. 10 (Reprinted) ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 HYPERTROPHIC CARDIOMYOPATHY decisions is derived primarily from non- contractile, structural, or regulatory activated protein kinase (PRKAG2) have randomized studies. I placed the great- functions).9,11-13,23-27 The physical simi- been reported to cause familial Wolff- est reliance on evidence-based investi- larity of these proteins makes it pos- Parkinson-White syndrome associated gational designs and large, statistically sible to regard the diverse HCM spec- with conduction abnormalities and powered and controlled studies, when trum as a single disease entity and LVH30,31 (because of glycogen accumu- available. primary sarcomere disorder. The mecha- lation in myocytes).31 This syndrome is nisms by which disease-causing muta- most appropriately regarded as a meta- RESULTS tions cause LV hypertrophy (LVH) and bolic storage disease distinct from HCM, Prevalence the HCM disease state are unresolved, which is caused by mutations in genes Epidemiological investigations with di- although several hypotheses have been encoding sarcomeric proteins. There- verse study designs have shown simi- suggested.28 fore, management and risk assessment lar estimates for prevalence of pheno- Three of the HCM-causing mutant of patients with Wolff-Parkinson- typically expressed HCM in the adult genes predominate, namely, ␤-myosin White syndrome and cardiac hypertro- general population at about 0.2% (1: heavy chain (the first identified), car- phy should not be predicated on data 500).20 Therefore, HCM is not rare and diac troponin T, and myosin-binding derived from patients with HCM. is the most common genetic cardiovas- protein C. The other genes each ac- Of potential importance for under- cular disease, with reports from many count for a minority of HCM cases, standing HCM pathophysiology are ge- countries. Nevertheless, a substantial namely, cardiac troponin I, regulatory netic animal models (ie, transgenic mice proportion of individuals harboring a and essential myosin light chains, titin, and rabbits)32-35 and spontaneously oc- mutant gene for HCM are probably un- ␣-tropomyosin, ␣-actin, and ␣-myosin curring animal diseases.36 In particu- detected clinically. Hypertrophic car- heavy chain. This diversity is com- lar, domestic cats with heart failure diomyopathy is, however, uncommon pounded by intragenic heterogeneity, commonly show a disease with clini- in routine cardiologic practice, affect- with more than 150 mutations identi- cal and morphologic features remark- ing no more than 1% of outpatients.21 fied, most of which are missense with a ably similar to HCM in humans.36 This limited exposure of clinicians to single amino acid residue substituted HCM understandably accounts for the with another.9,11-13,26,27 Molecular de- Diagnosis uncertainty that prevails regarding this fects responsible for HCM are usually Clinical diagnosis of HCM is estab- disease and its management. different in unrelated individuals, and lished most easily and reliably with 2-di- many other genes and mutations, each mensional echocardiography* by imag- Nomenclature accounting for a small proportion of fa- ing the hypertrophied but nondilated LV Since the first modern description in milial HCM, remain to be identified. chamber, in the absence of another car- 1958,1 HCM has been known by a con- Contemporary molecular genetic diac or systemic disease (eg, hyperten- fusing array of names, reflecting its clini- studies throughout the past decade have sion or aortic stenosis) capable of pro- cal heterogeneity and the skewed expe- provided important insights into the ducing the magnitude of hypertrophy rience of early investigators. Hypertrophic considerable clinical heterogeneity of evident (FIGURE 1and FIGURE 2A).19,22 cardiomyopathy22 is the preferred name HCM, including the preclinical diagno- Hypertrophic cardiomyopathy may be because it describes the overall disease sis of affected individuals without phe- initially suspected because of a heart spectrum without introducing mislead- notypic evidence of disease (ie, LVH murmur (occasionally during prepar- ing inferences that left ventricular (LV) by echocardiography or electrocar- ticipation sports examinations),43 posi- outflow tract obstruction
Load more

Recommended publications
  • Idiopathic Isolated Right Ventricular Apical Hypertrophy
    Acta Cardiol Sin 2018;34:288-290 Letter to the Editor doi: 10.6515/ACS.201805_34(3).20180122A Idiopathic Isolated Right Ventricular Apical Hypertrophy Debika Chatterjee1 and Pradeep Narayan2 INTRODUCTION creased RV compliance or RV dysfunction. Isolated right ventricular hypertrophy is extremely rare and reports in the literature are very sparse. We re- DISCUSSION port a case of focal apical right ventricular hypertrophy without involvement of the left ventricular cavity or the RV hypertrophy is usually reported in association inter-ventricular septum. with left ventricular hypertrophy which in turn could be secondary to hypertrophic cardiomyopathy (HCM), hy- pertensive left ventricular hypertrophy (LVH) or other CASE infiltrative conditions.1 However, isolated involvement of right ventricle is extremely rare in these conditions. The A 50 year old male, asymptomatic, normotensive only situation where isolated RV hypertrophy is seen is in patient on routine medical evaluation was found to have presence of idiopathic pulmonary artery hypertension. inverted T-waves on the electrocardiogram (Figure 1). However, the hypertrophy in these cases is rarely focal. He had no history of angina or any other symptoms. Isolated apical hypertrophic cardiomyopathy is an However, despite complete lack of symptoms, because extremely unusual nonobstructive hypertrophy that is of the abnormality on the electrocardiography (ECG) an localized to the cardiac apex.2 Even in these cases spar- echocardiography was carried out for further evaluation. ing of the left ventricular apex with involvement of only Echocardiography revealed focal hypertrophy of the the right ventricular apex is even more uncommon. The right ventricular (RV) apex almost obliterating the apex most common presenting symptom in patients with api- (Figure 2A) but sparing the inter-ventricular septum.
    [Show full text]
  • Cardiac Hypertrophy, Hypertrophic Cardiomyopathy, and Hyperparathyroidism-An Association
    Br Heart J: first published as 10.1136/hrt.54.5.539 on 1 November 1985. Downloaded from Br HeartJ 1985; 54: 539-42 Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism-an association C SYMONS, F FORTUNE, R A GREENBAUM, P DANDONA From the Departments of Cardiology and Human Metabolism, the Royal Free Hospital, London SUMMARY Left ventricular hypertrophy (symmetric, asymmetric, or hypertrophic cardio- myopathy) is an almost invariable accompaniment of primary hyperparathyroidism. Five of 18 patients with hypertrophic cardiomyopathy had raised serum concentrations of parathyroid hor- mone with normal serum calcium concentrations. Left ventricular hypertrophy did not occur in any of the six patients with hypercalcaemia alone. These relations suggest that parathyroid hormone rather than a rise in the extracellular calcium concentration is associated with a spectrum of left ventricular hypertrophy. All patients with increased circulating parathyroid hormone concentrations should have echo- cardiographic examination of the left ventricle. Conversely, parathyroid hormone concentrations should be measured in all patients with left ventricular hypertrophy from an unknown cause, especially those with hypertrophic cardiomyopathy. copyright. Calcium has powerful positive inotropic and chro- included.) Sixteen of these patients were found to notropic effects on cardiac muscle.' Any factor that have primary hyperparathyroidism and six of these promotes transmembrane calcium flux could be had had operations to remove either a parathyroid
    [Show full text]
  • Hypertension and Arrhythmia
    2005; 6: No. 24 HYPERTENSION AND ARRHYTHMIA Jean-Philippe Bagueta, Serap Erdineb, Jean-Michel Malliona From aCardiology and Hypertension Department, Grenoble University Hospital, BP 217, 38043 Grenoble cedex 09, France and b Istanbul University Cerrahpasa School of Medicine, Göztepe I. Orta Sok, 34 A/9 Istanbul, Turkey Correspondence: Jean-Philippe Baguet, Cardiologie et Hypertension artérielle, CHU de Grenoble - BP 217, 38043 Grenoble Cedex 09, France, tel +334767654.40, fax 334767655.59, [email protected] Introduction rapid or if there is some underlying problem with left ventricular Arrhythmia-both atrial and ventricular-is a common comorbidity function (either systolic or diastolic) (10). AF can also cause with hypertension (HT). Underlying mechanisms are many and episodes of dizziness or even syncope. Finally, in the various, including left ventricular hypertrophy (LVH), myocardial Framingham study, a correlation was observed between AF and ischemia, impaired left ventricular function and left atrial enlarge- mortality in both sexes, and this independently of other variables ment. Any form of arrhythmia may be associated with LVH but (11). ventricular arrhythmia is more common as well as being more dangerous. Treatment of atrial arrhythmia Preventing AF in hypertensive subjects depends on controlling Atrial arrhythmia blood pressure in order to reduce the risk of hypertensive car- Prevalence diomyopathy (or at least mitigating the consequences thereof). After supraventricular extrasystole, atrial fibrillation (AF) is the Antihypertensive therapy has been shown to reverse some of the next most common form of arrhythmia associated with HT. The structural cardiac changes caused by HT, including LVH and atri- relative risk of developing AF in HT is modest compared with other al enlargement (12, 13).
    [Show full text]
  • Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Impact, and Management
    Heart Failure Reviews (2019) 24:189–197 https://doi.org/10.1007/s10741-018-9752-6 Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management Lohit Garg 1 & Manasvi Gupta2 & Syed Rafay Ali Sabzwari1 & Sahil Agrawal3 & Manyoo Agarwal4 & Talha Nazir1 & Jeffrey Gordon1 & Babak Bozorgnia1 & Matthew W. Martinez1 Published online: 19 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hyper- trophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardio- graphic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes. Keywords Atrial fibrillation . Hypertrophic cardiomyopathy . Treatment . Antiarrhythmic agents Introduction amyloidosis) [3–5]. The clinical presentation of HCM is het- erogeneous and includes an asymptomatic state, heart failure Hypertrophic cardiomyopathy (HCM) is the most common syndrome due to diastolic dysfunction or left ventricular out- inherited cardiomyopathy due to mutation in one of the sev- flow (LVOT) obstruction, arrhythmias (atrial fibrillation and eral sarcomere genes and transmitted in autosomal dominant embolism), and sudden cardiac death [1, 6].
    [Show full text]
  • Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: an Overview of Current Knowledge
    Journal of Clinical Medicine Review Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge Beatrice Musumeci, Giacomo Tini , Domitilla Russo, Matteo Sclafani, Francesco Cava, Alessandro Tropea, Carmen Adduci, Francesca Palano, Pietro Francia and Camillo Autore * Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy; [email protected] (B.M.); [email protected] (G.T.); [email protected] (D.R.); [email protected] (M.S.); [email protected] (F.C.); [email protected] (A.T.); [email protected] (C.A.); [email protected] (F.P.); [email protected] (P.F.) * Correspondence: [email protected]; Tel.: +39-06-3377-5577 Abstract: While most patients with hypertrophic cardiomyopathy (HCM) show a relatively stable morphologic and clinical phenotype, in some others, progressive changes in the left ventricular (LV) wall thickness, cavity size, and function, defined, overall, as “LV remodeling”, may occur. The interplay of multiple pathophysiologic mechanisms, from genetic background to myocardial ischemia and fibrosis, is implicated in this process. Different patterns of LV remodeling have been recognized and are associated with a specific impact on the clinical course and management of the disease. These findings underline the need for and the importance of serial multimodal clinical and instrumental evaluations to identify and further characterize the LV remodeling phenomenon. A more complete definition of the stages of the disease may present a chance to improve the management of Citation: Musumeci, B.; Tini, G.; Russo, D.; Sclafani, M.; Cava, F.; HCM patients. Tropea, A.; Adduci, C.; Palano, F.; Francia, P.; Autore, C.
    [Show full text]
  • Hypertrophic Cardiomyopathy
    Clinical Update Adapted from: 2020 ACC/AHA Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy ACC/AHA Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)* HCM Hypertrophic Cardiomyopathy (HCM) is a Globally Prevalent & Common Genetic Heart Disease Inheritance Pattern Sex Distribution Disease Prevalence Triggers for Evaluation +/- +/+ Symptoms 50% 50% Cardiac Event Heart Murmur +/- Abnormal EKG Women diagnosed Estimated Cardiac Imaging Autosomal Dominant less commonly 1:200 – 1:500 Family Studies Other non-HCM Causes of LV Hypertrophy ⅔ have LVOTO Metabolic & Multi-organ Syndromes RASopathies Mitochondrial myopathies LV Outflow Tract Glycogen / Lysosomal storage diseases Amyloidosis Obstruction Sarcoidosis (LVOTO) Hemochromatosis Danon disease Secondary Causes Athlete’s heart HCM ⅓ do not have LVOTO Hypertension Valvular & subvalvular stenosis Abbreviations: EKG, indicates electrocardiogram; RAS, reticular activating system. 3 Ommen, SR et al. 2020 ACC/AHA Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Circulation. XXX:XX-XX. HCM Defining Hypertrophic Cardiomyopathy in 2020 • Morphologic expression confined solely to the heart • Characterized by left ventricular (LV) hypertrophy Basal anterior septum in continuity with the anterior free wall = most common • No other cardiac, systemic or metabolic disease capable of producing the magnitude of hypertrophy
    [Show full text]
  • Changes in Cardiac Geometry Due to Hypertrophy
    Changes in Cardiac Geometry Due to Hypertrophy By Marta Ellen Pedersen A Master’s Paper Submitted in Partial Fulfillment of The Requirements for the Degree of Master of Science in Clinical Exercise Physiology Dr. Joseph O’ Kroy Date University of Wisconsin-River Falls 2014 Introduction For any given body size, men have larger hearts than women, athletes have larger hearts than nonathletes, and often times, an enlarged heart is a symptom of an underlying disorder that is causing the heart to work harder than normal. This review will emphasize the differences between a pathologically enlarged heart and an athletically enlarged heart. Pathologically induced hypertrophy (myopathy) When heart cells get bigger, (often is the case when heart disease is present) the total heart works less efficiently. Some people suffer from conditions like hypertrophic cardiomyopathy, which includes significant heart muscle enlargement, and can be genetic or caused by high blood pressure. Cardiomyopathy decreases the size of the heart's chambers, reducing blood flow. Hypertrophy, or thickening, of the heart muscle can occur in response to increased stress on the heart. The most common causes of Cardiomyopathy are related to increased blood pressure. The extra work of pumping blood against the increased pressure causes the ventricle to thicken over time, the same way a body muscle increases in mass in response to weightlifting. Cardiomyopathy can occur in both the right and left atrium and the right and left ventricles. Blood travels through the right ventricle to the lungs. If conditions occur that decrease pulmonary circulation, extra stress can be placed on the right ventricle, and can lead to right ventricular myopathy.
    [Show full text]
  • How to Estimate Left Ventricular Hypertrophy in Hypertensive Patients
    Review 389 How to estimate left ventricular hypertrophy in hypertensive patients Dragan Lovic, Serap Erdine1, Alp Burak Çatakoğlu2 Clinic for internal disease, InterMedica; Nis-Serbia 1Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University; İstanbul-Turkey 2Department of Cardiology, Liv Hospital; İstanbul-Turkey ABSTRACT Left ventricular hypertrophy (LVH) is a structural remodeling of the heart developing as a response to volume and/or pressure overload. Previous studies have shown that hypertension is not an independent factor in the development of LVH and occurrence does not depend on the length and severity of hypertension, but the role played by other comorbidities such as triglycerides, age, gender, genetics, insulin resis- tance, obesity, physical inactivity, increased salt intake and chronic stress. LVH develops through three phases: adaptive, compensatory, and pathological phase. Contractile dysfunction is reversible in the first two phases and irreversible in the third. According to the Framingham study, LVH develops in 15-20% of patients with mild arterial hypertension, and in 50% of patients with severe hypertension. The pathophysiology of LVH includes hypertrophy of cardiomyocytes, interstitial and perivascular fibrosis, coronary microangiopathy and macroangiopathy. Individuals with LVH have 2-4 times higher risk of having adverse CV events compared to patients without LVH. (Anadolu Kardiyol Derg 2014; 14: 389-95) Key words: arterial hypertension, left ventricular hypertrophy, pathophysiology, cardiovascular events Introduction increases concurrently with the increase of body size in both genders. From puberty on, the growth rate of the heart is higher Arterial hypertension is a major cause of organ damage in men than in women, implying that men and women have spe- including the heart and left ventricular hypertrophy (LVH) is a cific cardiac growth curves.
    [Show full text]
  • Left Ventricular Hypertrophy in Aortic Valve Stenosis: Friend Or Foe?
    Downloaded from heart.bmj.com on February 14, 2011 - Published by group.bmj.com Editorial LVH response. Particularly striking has Left ventricular hypertrophy in been the observation that outcome is improved in animals undergoing aortic binding by blocking the hypertrophic aortic valve stenosis: friend or response to pressure overload.10 Although genetically modified animals have higher foe? left ventricular systolic stress than their wild-type counter mates, this has no consequence on long-term myocardial Raquel Yotti, Javier Bermejo performance. In fact, knock-out animals lived longer. The conventional conception ‘How wonderful that we have found (LVM) was found in 59% of patients from of physiological adaptation to pressure a paradox. Now we have some hope of an unselected cohort with asymptomatic overload as a teleological mechanism ’ making progress. AS. Multivariate analysis showed the to reduce wall stress thus calls for e Neils Böhr (1885 1962) independent predictive value of and inap- revision.11 12 Concentric remodelling (reduction of the propriate LVM, in addition to well estab- There are several mechanisms by which fl diameter/thickness ratio) and hyper- lished indices that in uence outcome in excessive LVH may be related to the 34 trophy (increase of massdleft ventricular AS such as baseline disease severity or outcome of patients with AS. It has been fi 5 hypertrophy; LVH) have been classically the degree of valve calci cation. Although shown that left ventricular systolic func- interpreted as the physiological mecha- a potentially maladaptive effect of hyper- tion declines as hypertrophy develops, 6 6 nisms used by the left ventricle to trophy in AS had already been reported, increasing the risk of heart failure.
    [Show full text]
  • Premature Ventricular Contractions Ralph Augostini, MD FACC FHRS
    Premature Ventricular Contractions Ralph Augostini, MD FACC FHRS Orlando, Florida – October 7-9, 2011 Premature Ventricular Contractions: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death J Am Coll Cardiol, 2006; 48:247-346. Background PVCs are ectopic impulses originating from an area distal to the His Purkinje system Most common ventricular arrhythmia Significance of PVCs is interpreted in the context of the underlying cardiac condition Ventricular ectopy leading to ventricular tachycardia (VT), which, in turn, can degenerate into ventricular fibrillation, is one of the common mechanisms for sudden cardiac death The treatment paradigm in the 1970s and 1980s was to eliminate PVCs in patients after myocardial infarction (MI). CAST and other studies demonstrated that eliminating PVCs with available anti-arrhythmic drugs increases the risk of death to patients without providing any measurable benefit Pathophysiology Three common mechanisms exist for PVCs, (1) automaticity, (2) reentry, and (3) triggered activity: Automaticity: The development of a new site of depolarization in non-nodal ventricular tissue. Reentry circuit: Reentry typically occurs when slow- conducting tissue (eg, post-infarction myocardium) is present adjacent to normal tissue. Triggered activity: Afterdepolarization can occur either during (early) or after (late) completion of repolarization. Early afterdepolarizations commonly are responsible for bradycardia associated PVCs, but also with ischemia and electrolyte disturbance. Triggered Fogoros: Electrophysiologic Testing. 3rd ed. Blackwell Scientific 1999; 158. Epidemiology Frequency The Framingham heart study (with 1-h ambulatory ECG) 1 or more PVCs per hour was 33% in men without coronary artery disease (CAD) and 32% in women without CAD Among patients with CAD, the prevalence rate of 1 or more PVCs was 58% in men and 49% in women.
    [Show full text]
  • Electrocardiographic Versus Echocardiographic Left Ventricular Hypertrophy in Severe Aortic Stenosis
    Journal of Clinical Medicine Article Electrocardiographic Versus Echocardiographic Left Ventricular Hypertrophy in Severe Aortic Stenosis Aleksandra Budkiewicz 1,† , Michał A. Surdacki 1,†, Aleksandra Gamrat 1, Katarzyna Trojanowicz 1, Andrzej Surdacki 2 and Bernadeta Chyrchel 2,* 1 Students’ Scientific Group, Second Department of Cardiology, Jagiellonian University Medical College, 2 Jakubowskiego Street, 30-688 Cracow, Poland; [email protected] (A.B.); [email protected] (M.A.S.); [email protected] (A.G.); [email protected] (K.T.) 2 Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Jakubowskiego Street, 30-688 Cracow, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-12-400-2250 † These first authors contributed equally to this work. Abstract: Although ECG used to be a traditional method to detect left ventricular hypertrophy (LVH), its importance has decreased over the years and echocardiography has emerged as a routine technique to diagnose LVH. Intriguingly, an independent negative prognostic effect of the “electrical” LVH (i.e., by ECG voltage criteria) beyond echocardiographic LVH was demonstrated both in hypertension and aortic stenosis (AS), the most prevalent heart valve disorder. Our aim was to estimate associations of the ECG-LVH voltage criteria with echocardiographic LVH and indices of AS severity. We retrospectively manually analyzed ECG tracings of 50 patients hospitalized in our center for severe isolated aortic stenosis, including 32 subjects with echocardiographic LVH. The sensitivity Citation: Budkiewicz, A.; Surdacki, of single traditional ECG-LVH criteria in detecting echocardiographic LVH was 9–34% and their M.A.; Gamrat, A.; Trojanowicz, K.; respective specificity averaged 78–100%.
    [Show full text]
  • Cardiac Enlargement in U.S. Firefighters
    CARDIAC ENLARGEMENT IN U.S. FIREFIGHTERS Findings and Recommendations from Non-Invasive Identification of Left Ventricular Hypertrophy/ Cardiomegaly in Firefighters July 19, 2017 ® © 2017 National Fallen Firefighters Foundation NATIONAL FALLEN FIREFIGHTERS FOUNDATION | CARDIAC ENLARGEMENT IN U.S. FIREFIGHTERS Acknowledgements Maria Korre, Sc.D. Harvard T.H. Chan School of Public Health Denise Smith, Ph.D. Skidmore College and Illinois Fire Service Institute Steven Moffatt, M.D. Public Safety Medical Stefanos Kales, M.D., M.P.H. Harvard T.H. Chan School of Public Health Funding was provided through the Federal Emergency Management Agency (FEMA) Assistance to Firefighters Grant (AFG) program’s award EMW-2011-FP-00663 (PI: Dr. S.N. Kales) and EMW-2013-FP-00749 (PI: Dr. D.L. Smith). 2 NATIONAL FALLEN FIREFIGHTERS FOUNDATION | CARDIAC ENLARGEMENT IN U.S. FIREFIGHTERS Contents Glossary of Terms ........................................................................................................................................ 4 Purpose and Objectives .............................................................................................................................. 5 Executive Summary ...................................................................................................................................... 6 Background .................................................................................................................................................. 8 Chapter 1 ......................................................................................................................................16
    [Show full text]